What if it's possible to revolutionize drug design?

We think it is

Shaping new possibilities for patients everywhere

Zymeworks is a clinical-stage biotechnology company united in creating disruptive therapeutic platforms and impactful biotherapeutics that return patients to their loved ones, disease free.

For Patients

Pipeline of Potential

Lead Product Candidates

Preclinical
Phase 1
Phase 2
Pivotal
Commercial Rights

Zanidatamab

HER2 x HER2 Bispecific Antibody

  • Azymetric™
Pivotal
BeiGene rights in Asia Pacific countries including China, South Korea, Australia, and New Zealand but excluding Japan.
  • Biliary Tract Cancers
  • Breast Cancer
  • Gastroesophageal Adenocarcinomas
  • Colorectal Cancer
  • HER2-Expressing Cancers
Full Details
  • 1st-Line Gastroesophageal Adenocarcinomas (HERIZON-GEA-01)
  • Pivotal

    Chemotherapy Combination

    Now Enrolling Patients
  • 2nd-Line Biliary Tract Cancers (HERIZON-BTC-01)
  • Pivotal

    Monotherapy

    FDA Breakthrough Therapy Designation

    Enrollment Complete
  • 1st-Line Gastrointestinal Cancers (Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer)
  • Phase 2

    Chemotherapy Combination

    Now Enrolling Patients
  • Late-Line Breast Cancer
  • Phase 2

    Combination with Palbociclib & Fulvestrant

    Now Enrolling Patients
  • HER2-Expressing Cancers
  • Phase 1

    Monotherapy & Chemotherapy Combination

    Now Enrolling Patients

    Zanidatamab Zovodotin

    HER2 x HER2 Bispecific Antibody Drug Conjugate (ADC)

    • Azymetric™
    • ZymeLink™
    Phase 1
    BeiGene rights in Asia Pacific countries including China, South Korea, Australia, and New Zealand but excluding Japan.
    • HER2-Expressing Cancers
    Full Details
  • HER2-Expressing Cancers
  • Phase 1

    Preclinical & Advanced Discovery

    Preclinical
    Phase 1
    Phase 2
    Pivotal
    Commercial Rights

    ZW191 - TOPO1i Antibody Drug Conjugate (ADC)

    TOPO1i Antibody Drug Conjugate (ADC)

    • ZymeLink™
    Preclinical
    • Ovarian Cancer & Gynecological Cancers
    Full Details

    ZW171 - 2+1 T-Cell Engaging Bispecific

    • Azymetric™
    Preclinical
    • Solid Tumors
    Full Details
    Explore Candidates

    Four platforms. Endless possibilities.

    Powerful, versatile protein engineering platforms for highly customized therapeutics including cytotoxic anti-tumor biologics, antibody drug conjugates, and immuno-oncology therapies.

    Explore Platforms

    One Zymeworks.

    Zymeworks employees

    innovate, act with integrity, collaborate, embrace diversity & care